These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28856537)

  • 1. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.
    Brugts JJ; Bertrand M; Remme W; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML; Boersma E
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):391-400. PubMed ID: 28856537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
    Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
    Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
    Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials.
    Radhoe SP; Boersma E; Bertrand M; Remme W; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML; Brugts JJ
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):131-139. PubMed ID: 36194352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
    Boos CJ
    Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
    Fox KM;
    Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
    Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
    Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.
    Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG
    Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.
    Niskanen L; Hedner T; Hansson L; Lanke J; Niklason A;
    Diabetes Care; 2001 Dec; 24(12):2091-6. PubMed ID: 11723089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
    Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
    Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
    Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The comparison of clinical effectiveness of perindopril and acebutolol in the primary hypertension treatment].
    Pieniazek W; Franczuk P; Janicki K
    Przegl Lek; 2001; 58(5):411-4. PubMed ID: 11603173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.